Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$55.45 USD

55.45
10,808,187

+1.13 (2.08%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

What to Expect from Big Pharmas After J&J's Solid Q3 Results?

Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

    Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

    At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.

      Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?

      Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

        Bristol-Myers Gets Priority Review for Opdivo Label Expansion

        Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.

          FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx

          Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.

            Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study

            Bristol-Myers Squibb (BMY) extended its strategic partnership with TARGET PharmaSolutions, Inc. for NASH study.

              Arpita Dutt headshot

              Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

              Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

                Non-Alcoholic Steatohepatitis 2017 Progress Update

                Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).

                  Seattle Genetics Inks Clinical Collaborations for Cancer Drug

                  Seattle Genetics (SGEN) announced two clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer.

                    Here's What's Has Happened in the HCV Space Lately

                    A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.

                      AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why

                      AbbVie's (ABBV) shares have gained an impressive 16.7% in the past month supported by a series of positive news for the company in the past few weeks.

                        Seattle Genetics' Adcetris Gets Breakthrough Therapy Status

                        Seattle Genetics' (SGEN) lymphoma drug, Adcetris has been granted Breakthrough Therapy Designation by the FDA for treating patients with advanced classical Hodgkin lymphoma with no prior treatments.

                          Arpita Dutt headshot

                          Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?

                          With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.

                            Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal

                            Infinity (INFI) expanded its existing clinical collaboration with Bristol-Myers Squibb for evaluating IPI-549 in combination with Opdivo to include patients with triple negative breast cancer.

                              Arpita Dutt headshot

                              Pharma Stock Roundup: J&J Drug Gets CRL, Label Expansion for Merck and BMY Drugs

                              Industry heavyweights like Johnson & Johnson (JNJ), Merck and Bristol-Myers were in the news related to regulatory updates.

                                Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer

                                AbbVie (ABBV) and Bristol-Myers Squibb entered into a deal to evaluate the combination of ABBV-399 and Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer.

                                  Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer

                                  Bristol-Myers Squibb Company (BMY) announced that the FDA has approved immuno-oncology drug Opdivo for liver cancer.

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update

                                    Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.

                                      Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA

                                      Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.

                                        Oncology Space in Focus this Week on ESMO Presentations

                                        There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.

                                          Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE

                                          Bristol-Myers Squibb Company (BMY) enters into a collaboration and license agreement with Halozyme Therapeutics, Inc. (HALO).

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO

                                            Key highlights this week include Teva's (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.

                                              Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate

                                              Nektar (NKTR) initiates phase I/II combo study on lead candidate NKTR-214 along with Tecentriq and Keytruda. The trial complements Nektar's ongoing PIVOT research clubbed with Opdivo.

                                                Bristol-Myers Reports Positive Results from Melanoma Study

                                                Bristol-Myers Squibb Company (BMY) announced encouraging results from a phase III study, CheckMate -238, on Opdivo.

                                                  Company News For Sep 12, 2017

                                                  Companies in the news are: TEVA,BMY,EFX,FB